Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
De‐Shen Wang(Sun Yat-sen University), Yuhong Li(Southwest Jiaotong University), Wenhua Fan(Capital Medical University), Jian‐wei Zhang(Sun Yat-sen University), Peirong Ding(Sun Yat-sen University), Chuanbo Xie(Sun Yat-sen University), Ying Jin(Harbin Medical University), Feng Wang(Sun Yat-sen University), Fen Feng(First People's Hospital of Foshan), Yanhong Deng(Sun Yat-sen University), Gong Chen(Guangdong Pharmaceutical University), Wei Wang(Unknown), Zhi‐Qiang Wang(Nanjing University of Chinese Medicine), Chao Ren(Sun Yat-sen University), Han‐lin Liang(Zhongshan People's Hospital), Rui‐Hua Xu(Sun Yat-sen University), Zhen-Hai Lu(Sun Yat-sen University), Si-Mei Shi(Sun Yat-sen University), Jiewen Peng(Zhongshan People's Hospital)
Cited by 28
Related Papers
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868